Contracts Finder · Tender

NHS Pharmaceuticals 2017_2

A public procurement published by NHS England via Contracts Finder.

Contracts FinderTender
Award value
£45.9m
Tender value
0
Suppliers
0
Awards
1
Notices
Tender
Stage

Overview

NHS Pharmaceuticals 2017_2. Period of framework agreement: The total maximum duration of the framework agreement to be no more than 36 months. Potential periods of call-offs under the framework agreement: CESW regions: 1.8.2018 to 28.2.2019 (7 months). NWLN regions: 1.8.2018 to 31.7.2019 (12 months). LSNE regions: 1.8.2018 to 31.1.2020 (18 months). Products on the framework include (but are not necessarily limited to): Abacavir, Abiraterone, Anidulafungin, Atovaquone, Bosentan, Ciclesonide, Drospirenone/Ethinylestradiol, Enfurvitide, Ethinylestradiol/Norelgestromin, Exenatide, Ezetimibe, Iloprost, Ivabradine, Mycophenolic acid, Nitisinone, Olopatadine, Oseltamivir, Parecoxib, Pegfilgr…

Key details

Source
Contracts Finder
Lifecycle stage
Tender
Status
active
CPV classification
33600000 — Pharmaceutical products
Currency
GBP
Total award value
Tender value
£45,850,500
First published
18 Jan 2018
Last updated
18 Jan 2018
View the original notice

Notice timeline

Every published notice in this procurement's lifecycle.

  1. Tender noticeNHS Pharmaceuticals 2017_2

Frameworks & programmes

More from NHS England

FAQs about this procurement

Who is the buyer for "NHS Pharmaceuticals 2017_2"?

NHS Pharmaceuticals 2017_2 is a UK public-sector procurement published by NHS England via Contracts Finder.

Has "NHS Pharmaceuticals 2017_2" been awarded?

No award has been recorded yet. The current lifecycle stage is "Tender".

What is "NHS Pharmaceuticals 2017_2" worth?

The reported tender value is £45,850,500.

When was "NHS Pharmaceuticals 2017_2" published?

It was first published on 18 Jan 2018 and last updated on 18 Jan 2018, across 1 notice.

Track procurements like this one

Enable monitors the entire UK public-contract pipeline — get alerts on buyers, suppliers and frameworks that matter to you.

Get in touch with Enable